{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:38:39Z","timestamp":1780468719031,"version":"3.54.1"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jns.2021.120094","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T11:19:34Z","timestamp":1639653574000},"page":"120094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder"],"prefix":"10.1016","volume":"432","author":[{"given":"Yu Kyung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Fuehrlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10258","key":"10.1016\/j.jns.2021.120094_bb0005","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2021.120094_bb0010","author":"Opioid Overdose Crisis"},{"key":"10.1016\/j.jns.2021.120094_bb0015","author":"Overdose Deaths Accelerating During COVID-19"},{"key":"10.1016\/j.jns.2021.120094_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17756\/jas.2021-050","article-title":"Opioid, cocaine and methamphetamine overdose crisis and deaths in 2021","volume":"7","author":"Gold","year":"2021","journal-title":"J. Addict. Sci."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5335","key":"10.1016\/j.jns.2021.120094_bb0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1126\/science.278.5335.52","article-title":"Drug abuse: hedonic homeostatic dysregulation","volume":"278","author":"Koob","year":"1997","journal-title":"Science."},{"issue":"4","key":"10.1016\/j.jns.2021.120094_bb0035","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1152\/physrev.00005.2009","article-title":"Reward processing by the opioid system in the brain","volume":"89","author":"Le Merrer","year":"2009","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.jns.2021.120094_bb0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jns.2021.120094_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001333.pub3","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"4","author":"Minozzi","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10118","key":"10.1016\/j.jns.2021.120094_bb0050","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jns.2021.120094_bb0055","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/j.1360-0443.2008.02249.x","article-title":"Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV\/AIDS","volume":"103","author":"Lawrinson","year":"2008","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.jns.2021.120094_bb0060","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction."},{"issue":"18","key":"10.1016\/j.jns.2021.120094_bb0065","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of Levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jns.2021.120094_bb0070","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1360-0443.2004.00752.x","article-title":"Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS)","volume":"99","author":"Godfrey","year":"2004","journal-title":"Addiction."},{"issue":"8","key":"10.1016\/j.jns.2021.120094_bb0075","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/cid\/ciw416","article-title":"Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis","volume":"63","author":"Low","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jns.2021.120094_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e5945","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis","volume":"345","author":"MacArthur","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jns.2021.120094_bb0085","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.jns.2021.120094_bb0090","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.jns.2021.120094_bb0095","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"Am. J. Public Health"},{"issue":"10182","key":"10.1016\/j.jns.2021.120094_bb0100","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet."},{"issue":"10208","key":"10.1016\/j.jns.2021.120094_bb0105","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","article-title":"Global patterns of opioid use and dependence: harms to populations, interventions, and future action","volume":"394","author":"Degenhardt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2021.120094_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117137","article-title":"Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): do homo sapiens acquire or have a reward deficiency syndrome?","volume":"418","author":"Gold","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.jns.2021.120094_bb0115","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","article-title":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study","volume":"2","author":"Kimber","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/j.jns.2021.120094_bb0120","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/add.13779","article-title":"Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England","volume":"112","author":"Marsden","year":"2017","journal-title":"Addiction."},{"issue":"12","key":"10.1016\/j.jns.2021.120094_bb0125","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2021.120094_bb0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","volume":"177","author":"Williams","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2021.120094_bb0135","doi-asserted-by":"crossref","first-page":"116718","DOI":"10.1016\/j.jns.2020.116718","article-title":"Treatment resistant opioid use disorder (TROUD): definition, rationale, and recommendations","volume":"411","author":"Patterson Silver Wolf","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2021.120094_bb0140","doi-asserted-by":"crossref","first-page":"117149","DOI":"10.1016\/j.jns.2020.117149","article-title":"Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: review of modalities and implications for treatment","volume":"418","author":"Mahoney","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"8","key":"10.1016\/j.jns.2021.120094_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136182","article-title":"The impact of accelerated right prefrontal high-frequency repetitive transcranial magnetic stimulation (rTMS) on Cue-reactivity: an fMRI study on craving in recently detoxified alcohol-dependent patients","volume":"10","author":"Herremans","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jns.2021.120094_bb0150","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jns.2021.120094_bb0155","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.brainres.2015.03.048","article-title":"Cortico-striatal circuits: novel therapeutic targets for substance use disorders","volume":"1628","author":"Kravitz","year":"2015","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11065-018-9393-5","article-title":"Efficacy of invasive and non-invasive brain modulation interventions for addiction","volume":"29","author":"Luigjes","year":"2019","journal-title":"Neuropsychol. Rev."},{"issue":"7","key":"10.1016\/j.jns.2021.120094_bb0165","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrn2169","article-title":"Is there a future for therapeutic use of transcranial magnetic stimulation?","volume":"8","author":"Ridding","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.jns.2021.120094_bb0170","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neuron.2007.06.026","article-title":"Transcranial Magnetic Stimulation: A Primer","volume":"55","author":"Hallett","year":"2007","journal-title":"Neuron."},{"issue":"4","key":"10.1016\/j.jns.2021.120094_bb0175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40473-017-0135-4","article-title":"Developing repetitive transcranial magnetic stimulation (rTMS) as a treatment tool for cocaine use disorder: a series of six translational studies","volume":"4","author":"Hanlon","year":"2017","journal-title":"Curr. Behav. Neurosci. Rep."},{"issue":"5","key":"10.1016\/j.jns.2021.120094_bb0180","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/09540261.2011.618827","article-title":"Repetitive transcranial magnetic stimulation and drug addiction","volume":"23","author":"Barr","year":"2011","journal-title":"Int. Rev. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0185","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1176\/appi.neuropsych.13010013","article-title":"Comparison of anticraving efficacy of right and left repetitive transcranial magnetic stimulation in alcohol dependence: a randomized double-blind study","volume":"27","author":"Mishra","year":"2015","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/nyas.12479","article-title":"Transcranial magnetic stimulation in the treatment of substance addiction","volume":"1327","author":"Gorelick","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"11","key":"10.1016\/j.jns.2021.120094_bb0195","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.biopsych.2007.01.018","article-title":"Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial","volume":"62","author":"O\u2019Reardon","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/YCT.0000000000000500","article-title":"Crossover to bilateral repetitive transcranial magnetic stimulation: a potential strategy when patients are not responding to unilateral left-sided high-frequency repetitive transcranial magnetic stimulation","volume":"35","author":"Cristancho","year":"2019","journal-title":"J. ECT"},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0205","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.brs.2018.01.020","article-title":"rTMS for major depression: treatment outcomes at an academic medical center","volume":"11","author":"Cristancho","year":"2018","journal-title":"Brain Stimul."},{"issue":"5","key":"10.1016\/j.jns.2021.120094_bb0210","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.euroneuro.2017.03.008","article-title":"Deep transcranial magnetic stimulation of the dorsolateral prefrontal cortex in alcohol use disorder patients: effects on dopamine transporter availability and alcohol intake","volume":"27","author":"Addolorato","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.jns.2021.120094_bb0215","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.biopsych.2014.05.020","article-title":"Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial","volume":"76","author":"Dinur-Klein","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jns.2021.120094_bb0220","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neubiorev.2019.06.007","article-title":"Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: a consensus paper on the present state of the science and the road ahead","volume":"104","author":"Ekhtiari","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"8","key":"10.1016\/j.jns.2021.120094_bb0225","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.biopsych.2013.01.003","article-title":"Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine Cue craving","volume":"73","author":"Li","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0230","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.euroneuro.2015.11.011","article-title":"Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: a pilot study","volume":"26","author":"Terraneo","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jns.2021.120094_bb0235","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pnpbp.2013.10.019","article-title":"Repetitive transcranial magnetic stimulation reduces cigarette consumption in schizophrenia patients","volume":"49","author":"Prikryl","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jns.2021.120094_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102809","article-title":"The effects of repetitive transcranial magnetic stimulation on cue-induced craving in male patients with heroin use disorder","volume":"56","author":"Liu","year":"2020","journal-title":"EBioMedicine."},{"issue":"10131","key":"10.1016\/j.jns.2021.120094_bb0245","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(18)30295-2","article-title":"Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial","volume":"391","author":"Blumberger","year":"2018","journal-title":"Lancet."},{"issue":"7","key":"10.1016\/j.jns.2021.120094_bb0250","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/da.23004","article-title":"A systematic review and meta-analysis on the effects of transcranial direct current stimulation in depressive episodes","volume":"37","author":"Razza","year":"2020","journal-title":"Depress. Anxiety"},{"issue":"5","key":"10.1016\/j.jns.2021.120094_bb0255","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.brs.2016.06.004","article-title":"Safety of transcranial direct current stimulation: evidence based update 2016","volume":"9","author":"Bikson","year":"2016","journal-title":"Brain Stimul."},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0260","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.brs.2011.03.002","article-title":"Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions","volume":"5","author":"Brunoni","year":"2012","journal-title":"Brain Stimul."},{"key":"10.1016\/j.jns.2021.120094_bb0265","author":"Abrantes"},{"key":"10.1016\/j.jns.2021.120094_bb0270","author":"Camchong"},{"key":"10.1016\/j.jns.2021.120094_bb0275","author":"Combining"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0280","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev.neuro.29.051605.112824","article-title":"Deep brain stimulation","volume":"29","author":"Perlmutter","year":"2006","journal-title":"Annu. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.jns.2021.120094_bb0285","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3171\/jns.2007.106.4.621","article-title":"Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders","volume":"106","author":"Kenney","year":"2007","journal-title":"J. Neurosurg."},{"issue":"04","key":"10.1016\/j.jns.2021.120094_bb0290","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-0042-104507","article-title":"Nucleus Accumbens deep brain stimulation for alcohol addiction \u2013 safety and clinical long-term results of a pilot trial","volume":"49","author":"M\u00fcller","year":"2016","journal-title":"Pharmacopsychiatry."},{"issue":"11","key":"10.1016\/j.jns.2021.120094_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2011.02.012","article-title":"Deep brain stimulation of nucleus accumbens on heroin-seeking behaviors: a case report","volume":"69","author":"Zhou","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2021.120094_bb0300","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/mp.2012.196","article-title":"Deep brain stimulation of the nucleus accumbens and its usefulness in severe opioid addiction","volume":"19","author":"Kuhn","year":"2014","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2021.120094_bb0305","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.3171\/2018.5.FOCUS18163","article-title":"Deep brain stimulation for the treatment of drug addiction","volume":"45","author":"Wang","year":"2018","journal-title":"Neurosurg. Focus FOC"},{"issue":"6","key":"10.1016\/j.jns.2021.120094_bb0310","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/mp.2011.114","article-title":"Deep brain stimulation in addiction: a review of potential brain targets","volume":"17","author":"Luigjes","year":"2012","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2021.120094_bb0315","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s10143-020-01415-y","article-title":"Outcomes of deep brain stimulation surgery for substance use disorder: a systematic review","volume":"44","author":"Hassan","year":"2021","journal-title":"Neurosurg. Rev."},{"issue":"2","key":"10.1016\/j.jns.2021.120094_bb0320","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/ajad.12674","article-title":"A review of brain stimulation methods to treat substance use disorders","volume":"27","author":"Coles","year":"2018","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.jns.2021.120094_bb0325","author":"Tomycz"},{"key":"10.1016\/j.jns.2021.120094_bb0330","author":"Rezai"},{"issue":"2","key":"10.1016\/j.jns.2021.120094_bb0335","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s40473-014-0010-5","article-title":"Vagus nerve stimulation","volume":"1","author":"Howland","year":"2014","journal-title":"Curr. Behav. Neurosci. Rep."},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0340","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.brs.2015.11.003","article-title":"Transcutaneous Vagus nerve stimulation (tVNS) for treatment of drug-resistant epilepsy: a randomized, double-blind clinical trial (cMPsE02)","volume":"9","author":"Bauer","year":"2016","journal-title":"Brain Stimul."},{"issue":"5","key":"10.1016\/j.jns.2021.120094_bb0345","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12178","article-title":"Chronic Vagus nerve stimulation significantly improves quality of life in treatment-resistant major depression","volume":"79","author":"Conway","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.jns.2021.120094_bb0350","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1176\/appi.ajp.2017.16010034","article-title":"A 5-year observational study of patients with treatment-resistant depression treated with Vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality","volume":"174","author":"Aaronson","year":"2017","journal-title":"Am. J. Psychiatr."},{"issue":"8","key":"10.1016\/j.jns.2021.120094_bb0355","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1097\/j.pain.0000000000000930","article-title":"Modulation of brainstem activity and connectivity by respiratory-gated auricular vagal afferent nerve stimulation in migraine patients","volume":"158","author":"Garcia","year":"2017","journal-title":"Pain."},{"key":"10.1016\/j.jns.2021.120094_bb0360","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/NDT.S196665","article-title":"Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression","volume":"15","author":"Kumar","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0365","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1101\/lm.043539.116","article-title":"Vagus nerve stimulation reduces cocaine seeking and alters plasticity in the extinction network","volume":"24","author":"Childs","year":"2017","journal-title":"Learn. Mem."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0370","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neulet.2011.02.059","article-title":"Vagus nerve stimulation inhibits heroin-seeking behavior induced by heroin priming or heroin-associated cues in rats","volume":"494","author":"Liu","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jns.2021.120094_bb0375","author":"Bremner"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0380","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/00952990.2017.1295459","article-title":"Neuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment","volume":"44","author":"Miranda","year":"2018","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.jns.2021.120094_bb0385","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.yebeh.2019.03.025","article-title":"Effect of a 10-day transcutaneous trigeminal nerve stimulation (TNS) protocol for depression amelioration: a randomized, double blind, and sham-controlled phase II clinical trial","volume":"95","author":"Generoso","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jns.2021.120094_bb0390","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuroscience.2017.05.012","article-title":"Percutaneous electrical nerve field stimulation modulates central pain pathways and attenuates post-inflammatory visceral and somatic hyperalgesia in rats","volume":"356","author":"Babygirija","year":"2017","journal-title":"Neuroscience."},{"issue":"12","key":"10.1016\/j.jns.2021.120094_bb0395","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/jamaneurol.2017.3098","article-title":"Safety and efficacy of focused ultrasound Thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial","volume":"74","author":"Bond","year":"2017","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.jns.2021.120094_bb0400","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1056\/NEJMoa1600159","article-title":"A randomized trial of focused ultrasound Thalamotomy for essential tremor","volume":"375","author":"Elias","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jns.2021.120094_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2019.01.019","article-title":"Manipulation of subcortical and deep cortical activity in the primate brain using transcranial focused ultrasound stimulation","volume":"101","author":"Folloni","year":"2019","journal-title":"Neuron."},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0410","first-page":"187","article-title":"A review on brain stimulation using Low intensity focused ultrasound","volume":"7","author":"Rezayat","year":"2016","journal-title":"Basic Clin. Neurosci."},{"issue":"9","key":"10.1016\/j.jns.2021.120094_bb0415","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/s41380-020-0737-1","article-title":"Magnetic resonance-guided focused ultrasound capsulotomy for refractory obsessive compulsive disorder and major depressive disorder: clinical and imaging results from two phase I trials","volume":"25","author":"Davidson","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2017.05.008","article-title":"Treatment of major depressive disorder via magnetic resonance-guided focused ultrasound surgery","volume":"83","author":"Kim","year":"2018","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2021.120094_bb0425","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1503\/jpn.170188","article-title":"A study of novel bilateral thermal capsulotomy with focused ultrasound for treatment-refractory obsessive-compulsive disorder: 2-year follow-up","volume":"43","author":"Kim","year":"2018","journal-title":"J. Psychiatry Neurosci."},{"issue":"10","key":"10.1016\/j.jns.2021.120094_bb0430","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/mp.2014.154","article-title":"Bilateral thermal capsulotomy with MR-guided focused ultrasound for patients with treatment-refractory obsessive-compulsive disorder: a proof-of-concept study","volume":"20","author":"Jung","year":"2015","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0435","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41582-020-00418-z","article-title":"Applications of focused ultrasound in the brain: from thermoablation to drug delivery","volume":"17","author":"Meng","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2021.120094_bb0440","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/bja\/aev302","article-title":"The use of high-intensity focused ultrasound as a novel treatment for painful conditions\u2014a description and narrative review of the literature","volume":"115","author":"Brown","year":"2015","journal-title":"BJA"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0445","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s13311-018-00691-3","article-title":"Focused ultrasound for neuromodulation","volume":"16","author":"Darrow","year":"2019","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.jns.2021.120094_bb0450","author":"Rezai"},{"issue":"2","key":"10.1016\/j.jns.2021.120094_bb0455","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jns.2021.120094_bb0460","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic hallucinogens in the treatment of addictions","volume":"64","author":"Bogenschutz","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jns.2021.120094_bb0465","article-title":"Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016\u20132020) systematic review of preclinical and human studies","author":"Rodrigues","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"16","key":"10.1016\/j.jns.2021.120094_bb0470","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron."},{"issue":"11","key":"10.1016\/j.jns.2021.120094_bb0475","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.jns.2021.120094_bb0480","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","article-title":"The current status of psychedelics in psychiatry","volume":"78","author":"Nutt","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0485","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bcp.2007.07.018","article-title":"The behavioral pharmacology of hallucinogens","volume":"75","author":"Fantegrossi","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.jns.2021.120094_bb0490","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/npp.2017.86","article-title":"Modern clinical research on LSD","volume":"42","author":"Liechti","year":"2017","journal-title":"Neuropsychopharmacology."},{"issue":"943","key":"10.1016\/j.jns.2021.120094_bb0495","article-title":"Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials","volume":"10","author":"Fuentes","year":"2020","journal-title":"Front. Psychiatry"},{"issue":"7","key":"10.1016\/j.jns.2021.120094_bb0500","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.jns.2021.120094_bb0505","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study","volume":"28","author":"Savage","year":"1973","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.jns.2021.120094_bb0510","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.jns.2021.120094_bb0515","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.jns.2021.120094_bb0520","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"974","key":"10.1016\/j.jns.2021.120094_bb0525","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0530","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.jns.2021.120094_bb0535","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2021.120094_bb0540","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0545","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"11","key":"10.1016\/j.jns.2021.120094_bb0550","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0555","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jns.2021.120094_bb0560","author":"Brown"},{"key":"10.1016\/j.jns.2021.120094_bb0565","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neubiorev.2017.03.010","article-title":"Ketamine as a rapid-acting agent for suicidal ideation: a meta-analysis","volume":"77","author":"Bartoli","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jns.2021.120094_bb0570","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2147\/NDT.S117146","article-title":"Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies","volume":"12","author":"Han","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"4","key":"10.1016\/j.jns.2021.120094_bb0575","first-page":"1157","article-title":"Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression","volume":"238","author":"Siegel","year":"2021","journal-title":"Psychopharmacology."},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0580","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/15622975.2016.1142607","article-title":"Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: a pilot randomised controlled trial","volume":"17","author":"Lenze","year":"2016","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jns.2021.120094_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112628","article-title":"Ketamine and rapid acting antidepressants: are we ready to cure, rather than treat depression?","volume":"390","author":"Abdallah","year":"2020","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jns.2021.120094_bb0590","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.neubiorev.2021.05.006","article-title":"Therapeutic potential of ketamine for alcohol use disorder","volume":"126","author":"Worrell","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0595","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","article-title":"Association of Combined Naltrexone and Ketamine with Depressive Symptoms in a case series of patients with depression and alcohol use disorder","volume":"76","author":"Yoon","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0600","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence","volume":"39","author":"Krupitsky","year":"2007","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.jns.2021.120094_bb0605","author":"Garland"},{"key":"10.1016\/j.jns.2021.120094_bb0610","author":"Jones"},{"issue":"597","key":"10.1016\/j.jns.2021.120094_bb0615","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe1376","article-title":"A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression","volume":"13","author":"Nagele","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0620","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamapsychiatry.2016.2586","article-title":"Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough","volume":"74","author":"Conway","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0625","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biopsych.2014.11.016","article-title":"Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial","volume":"78","author":"Nagele","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0630","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/15672050113109990001","article-title":"Ibogaine in the treatment of substance dependence","volume":"6","author":"Brown","year":"2013","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.jns.2021.120094_bb0635","series-title":"The Alkaloids: Chemistry and Biology","first-page":"155","article-title":"Chapter 8 Ibogaine in the treatment of heroin withdrawal","author":"Mash","year":"2001"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0640","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jep.2007.08.034","article-title":"The ibogaine medical subculture","volume":"115","author":"Alper","year":"2008","journal-title":"J. Ethnopharmacol."},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0645","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/105504999305848","article-title":"Treatment of acute opioid withdrawal with ibogaine","volume":"8","author":"Alper","year":"1999","journal-title":"Am. J. Addict."},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0650","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/02791072.2018.1447175","article-title":"Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing Ibogaine","volume":"50","author":"Malcolm","year":"2018","journal-title":"J. Psychoactive Drugs"},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0655","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1556\/2054.2020.00133","article-title":"Novel treatment of opioid use disorder using ibogaine and iboga in two adults","volume":"4","author":"Wilson","year":"2021","journal-title":"J. Psychedelic Stud."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0660","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/00952990.2017.1320802","article-title":"Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes","volume":"44","author":"Brown","year":"2018","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.jns.2021.120094_bb0665","author":"Buoso"},{"key":"10.1016\/j.jns.2021.120094_bb0670","author":"Dos Santos"},{"issue":"5","key":"10.1016\/j.jns.2021.120094_bb0675","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.71","article-title":"Ibogaine and addiction in the animal model, a systematic review and meta-analysis","volume":"6","author":"Belgers","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jns.2021.120094_bb0680","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/SAR.S164261","article-title":"Current perspectives on the impact of Kratom use","volume":"10","author":"Veltri","year":"2019","journal-title":"Subst. Abus. Rehabil."},{"key":"10.1016\/j.jns.2021.120094_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107849","article-title":"Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic","volume":"208","author":"Garcia-Romeu","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jns.2021.120094_bb0690","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.drugalcdep.2019.05.005","article-title":"Kratom as a substitute for opioids: results from an online survey","volume":"202","author":"Coe","year":"2019","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0695","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/20009666.2018.1468693","article-title":"Kratom: a dangerous player in the opioid crisis","volume":"8","author":"Tayabali","year":"2018","journal-title":"J. Commun. Hosp. Intern. Med. Perspect."},{"issue":"7","key":"10.1016\/j.jns.2021.120094_bb0700","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/phar.2280","article-title":"Kratom use and toxicities in the United States","volume":"39","author":"Eggleston","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.jns.2021.120094_bb0705","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00213-007-0703-5","article-title":"The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review","volume":"191","author":"Parrott","year":"2007","journal-title":"Psychopharmacology."},{"issue":"7","key":"10.1016\/j.jns.2021.120094_bb0710","first-page":"917","article-title":"The pharmacology and toxicology of \u201cecstasy\u201d (MDMA) and related drugs","volume":"165","author":"Kalant","year":"2001","journal-title":"CMAJ."},{"issue":"6","key":"10.1016\/j.jns.2021.120094_bb0715","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"issue":"522","key":"10.1016\/j.jns.2021.120094_bb0720","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw6435","article-title":"Distinct neural mechanisms for the prosocial and rewarding properties of MDMA","volume":"11","author":"Heifets","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0725","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41386-020-00803-8","article-title":"Better living through chemistry: MDMA\u2019s prosocial mechanism as a starting point for improved therapeutics","volume":"46","author":"Heifets","year":"2021","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.jns.2021.120094_bb0730","article-title":"The epidemiology of mescaline use: pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects","author":"Uthaug","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0735","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/15733998113099990003","article-title":"Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada","volume":"6","author":"Thomas","year":"2013","journal-title":"Curr. Drug Abuse Rev."},{"issue":"2","key":"10.1016\/j.jns.2021.120094_bb0740","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acsptsci.1c00018","article-title":"Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes","volume":"4","author":"Agin-Liebes","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"4","key":"10.1016\/j.jns.2021.120094_bb0745","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2018","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jns.2021.120094_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.04.053","article-title":"Ayahuasca, an ancient substance with traditional and contemporary use in neuropsychiatry and neuroscience","volume":"121","author":"dos Santos","year":"2021","journal-title":"Epilepsy Behav."},{"issue":"136","key":"10.1016\/j.jns.2021.120094_bb0755","article-title":"Assessment of alcohol and tobacco use disorders among religious users of Ayahuasca","volume":"9","author":"Barbosa","year":"2018","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0760","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.brainresrev.2004.12.033","article-title":"The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence","volume":"49","author":"Heidbreder","year":"2005","journal-title":"Brain Res. Rev."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0765","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejphar.2005.09.038","article-title":"Novel pharmacotherapeutic targets for the management of drug addiction","volume":"526","author":"Heidbreder","year":"2005","journal-title":"Eur. J. Pharmacol."},{"issue":"14","key":"10.1016\/j.jns.2021.120094_bb0770","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1111\/bph.13757","article-title":"Oxytocin and opioid addiction revisited: old drug, new applications","volume":"175","author":"Zanos","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.jns.2021.120094_bb0775","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00439-012-1172-4","article-title":"The genetics of the opioid system and specific drug addictions","volume":"131","author":"Levran","year":"2012","journal-title":"Hum. Genet."},{"issue":"7","key":"10.1016\/j.jns.2021.120094_bb0780","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrg1635","article-title":"The genetics of addictions: uncovering the genes","volume":"6","author":"Goldman","year":"2005","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0785","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12424","article-title":"MicroRNAs regulate synaptic plasticity underlying drug addiction","volume":"17","author":"Smith","year":"2018","journal-title":"Genes Brain Behav."},{"issue":"12","key":"10.1016\/j.jns.2021.120094_bb0790","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1080\/21645515.2016.1212785","article-title":"Biologics to treat substance use disorders: current status and new directions","volume":"12","author":"Pravetoni","year":"2016","journal-title":"Hum. Vacc. Immunother."},{"key":"10.1016\/j.jns.2021.120094_bb0795","series-title":"International Review of Neurobiology","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/bs.irn.2016.02.009","article-title":"Chapter eight - animal models and the development of vaccines to treat substance use disorders","author":"Ohia-Nwoko","year":"2016"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0800","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biopsych.2009.08.031","article-title":"Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans","volume":"67","author":"Haney","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0805","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nyas.14329","article-title":"Current status of immunotherapies for addiction","volume":"1489","author":"Xu","year":"2021","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jns.2021.120094_bb0810","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41541-017-0013-9","article-title":"Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid a as an adjuvant","volume":"2","author":"Torres","year":"2017","journal-title":"NPJ Vacc."},{"issue":"3","key":"10.1016\/j.jns.2021.120094_bb0815","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/pr.117.013904","article-title":"Conjugate vaccine immunotherapy for substance use disorder","volume":"69","author":"Bremer","year":"2017","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.jns.2021.120094_bb0820","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1038\/npp.2013.114","article-title":"Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter","volume":"38","author":"Maoz","year":"2013","journal-title":"Neuropsychopharmacology."},{"issue":"11","key":"10.1016\/j.jns.2021.120094_bb0825","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239780","article-title":"Cocaine vaccine dAd5GNE protects against moderate daily and high-dose \u201cbinge\u201d cocaine use","volume":"15","author":"Havlicek","year":"2020","journal-title":"PLoS One"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:59:14Z","timestamp":1758383954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21027969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":165,"alternative-id":["S0022510X21027969"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.120094","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.120094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120094"}}